Update date
04 Mar 2025
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2025.
Shareable Research Card
NEVRO CORP has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q4 2024. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
04 Mar 2025
Page type
Company facts
Latest period
Q1 2025
SEC-backed company facts were refreshed from filings filed on 04 Mar 2025.
Benchmark Context
Return On Equity is up about 45% versus the comparable prior period. It sits inside the middle range of the current industry benchmark sample.
Compared with
Compared with NEVRO CORP's recent history and the latest same-industry benchmark sample for the same metric.
Why this is notable
Use the history link to verify the prior-period change, then compare that metric with the current industry middle range if you want broader context.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Plain-English Guide
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2025-02-27) highlights Return On Equity -43.3%, Return On Assets -19.1%, and Operating Margin -30.9%.
Use these links to compare NEVRO CORP against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: -3.9%
Latest value: -23%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
24.0/100
Weak Confidence high
-43%
Metric score 0.0/100
-19%
Metric score 0.0/100
Quick Ratio
Return On Equity, Return On Assets, and Operating Margin
Return On Equity
-43%
YoY: +45%
Industry median: -17% (n=179)
Return On Assets
-19%
YoY: +28%
Industry median: -34% (n=178)
Operating Margin
-31%
YoY: +32%
Industry median: -18% (n=127)
Current Ratio
4.62x
YoY: -27%
Industry median: 2.36x (n=176)
Quick Ratio
1.62x
YoY: -27%
Industry median: 1.49x (n=146)
Debt-to-equity
1.22x
YoY: +23%
Industry median: 0.46x (n=133)
Revenues YoY
-3.9%
YoY:
Industry median: 15% (n=128)
NetIncomeLoss YoY
-23%
YoY:
Industry median: 0.49% (n=168)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -43% | +45% |
| Return On Assets | -19% | +28% |
| Operating Margin | -31% | +32% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 4.62x | -27% |
| Quick Ratio | 1.62x | -27% |
| Debt-to-equity | 1.22x | +23% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -3.9% | |
| NetIncomeLoss YoY | -23% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 37,878,565 | +3.1% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.